Roche FY Revenues: $49.1 billion (+8%) FY Earnings: $8.5 billion (-22%) Comments: Pharma sales were up 11% (8% in CHF and U.S. dollars). The company achieved record sales for the year with continued growth for Avastin, Herceptin, MabThera/Rituxan, Tarceva and Xeloda, as well as Tamiflu and Lucentis sales. Genentech contributed 9% to results. Roche obtained full ownership of Genentech in March 2009. For the year, restructuring and integration costs were $2.3 billion, related to the disco...